Alphabet's Isomorphic Labs to Launch Human Trials for AI-Designed Drugs
-
最新报道：Alphabet's Isomorphic Labs has initiated human trials for its first AI-designed drug candidates, marking a significant milestone in AI-driven drug discovery. The subsidiary, spun off from DeepMind in 2021, leverages machine learning to accelerate pharmaceutical development. While specific disease targets remain undisclosed, the trials demonstrate progress in Isomorphic's mission to revolutionize medicine through computational biology. The move follows Alphabet's broader push into healthcare AI, including DeepMind's AlphaFold protein-structure predictions. Industry analysts note this positions Alphabet alongside biotech firms like Recursion Pharmaceuticals in the competitive AI drug development space, though commercial viability may take years to assess.
下一篇
BONK Meme Coin Surges 20% Daily Amid ETF Speculation
- Bonk, the dog-themed meme coin on Solana, surged over 20% in the past 24 hours amid specul...
24小时热点
热点专题
415697